Timothy Skalland

Datos Biográficos

ID90466
NOMBRETimothy Skalland
NOMBRESTimothy
APELLIDOSkalland
FIRMASKALLAND T
AFILIACIONESFred Hutch Cancer Center
ORCID0000-0001-8317-7685
VERIFICADOSí
TOTAL DE OBRAS3
TOTAL DE CITAS0
TOTAL COMO AUTOR3
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2023
AÑO MÁS RECIENTE DE PUBLICACIÓN2026
ÍNDICE H0

  • Migration and its impact on universal HIV testing and treatment in the HPTN 071 (PopART) study communities

    Open AccessDavid Macleod, Sian Floyd et al.ARTICLEPLOS Global Public Health2026

    Migrants have been identified as a population left behind by the AIDS (Acquired Immune Deficiency Syndrome) response, with evidence showing poorer HIV (Human Immunodeficiency Virus) outcomes and reduced intervention effectiveness in mobile populations. We used data from the HPTN 071 (PopART) trial (ClinicalTrials.gov number, NCT01900977) to investigate migration and HIV-related indicators, assessing whether community migration influenced PopART t…

  • Vaccine Hesitancy at Nine Community Sites Across the United States, Early in Covid-19 Vaccine Rollout

    Open AccessAneeka Ratnayake, Julie H Hernandez et al.ARTICLEJournal of Racial and Ethnic…2024Referencias: 46

    Background Vaccine hesitancy has been a significant concern throughout the COVID-19 pandemic. Vaccine hesitancy can be attributed to lack of confidence in vaccines, complacency about the health threat, or lack of convenience of vaccination. To date, few studies have used methods designed to include populations underrepresented in research when identifying factors associated with vaccine hesitancy. Methods Between January and July 2021, potential …

  • Population-level viremia predicts HIV incidence at the community level across the Universal Testing and Treatment Trials in eastern and southern Africa

    Open AccessJoseph Larmarange, Pamela Bachanas et al.ARTICLEPLOS Global Public Health2023

    Universal HIV testing and treatment (UTT) strategies aim to optimize population-level benefits of antiretroviral treatment. Between 2012 and 2018, four large community randomized trials were conducted in eastern and southern Africa. While their results were broadly consistent showing decreased population-level viremia reduces HIV incidence, it remains unclear how much HIV incidence can be reduced by increasing suppression among people living with…